262 related articles for article (PubMed ID: 33128206)
1. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.
Li X; Zhou D; Chi X; Li Q; Wang L; Lu B; Mao D; Wu Q; Wang X; Zhang M; Xue J; Li Y; Lu W; Guo J; Jiang F; Zhang X; Li Z; Yang X; Guo H; Gan D; He L; Luo L; Zhang L; Du H; Ye Y
Hepatol Int; 2020 Dec; 14(6):985-996. PubMed ID: 33128206
[TBL] [Abstract][Full Text] [Related]
2. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
Ye YA; Li XK; Zhou DQ; Chi XL; Li Q; Wang L; Lu BJ; Mao DW; Wu QK; Wang XB; Zhang MX; Xue JD; Li Y; Lu W; Guo JC; Jiang F; Zhang XW; Du HB; Yang XZ; Guo H; Gan DN; Li ZG
Chin J Integr Med; 2018 Sep; 24(9):653-660. PubMed ID: 30209792
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
Li X; Zhang L; Qiu M; Huang Y; Xiao H; Lu B; Jiang Y; Long F; Lin H; He J; Wu Q; Zhang M; Wang L; Zhu X; Gong M; Sun X; Sun J; Sun F; Lu W; Xu W; Chen G; Li Z; Gan D; Yang X; Du H; Ye Y
Trials; 2020 Aug; 21(1):708. PubMed ID: 32787905
[TBL] [Abstract][Full Text] [Related]
4. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
5. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
Xu JH; Fan YN; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
[TBL] [Abstract][Full Text] [Related]
6. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial.
Li XK; Zhang MX; Shao FZ; Zhou DQ; Xue JD; Liu TJ; Chi XL; Lu BJ; Wang XB; Li Q; Li J; Mao DW; Yang HS; Yang HZ; Zhao WX; Li Y; Zhang GL; Zhao YM; Zou JD; Liu MY; Zhang KK; Yang XZ; Gan DN; Li Y; Zhang P; Li ZG; Li S; Ye YA
Chin J Integr Med; 2020 May; 26(5):330-338. PubMed ID: 31919749
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
8. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
10. [Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].
Xu JH; Yu YY; Si CW; Zeng Z; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J; Xu ZN
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):881-5. PubMed ID: 24636286
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
[TBL] [Abstract][Full Text] [Related]
14. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.
Yang JM; Chen LP; Wang YJ; Lyu B; Zhao H; Shang ZY; Li J; Fan ZY; Wu SD; Ming X; Li X; Huang SP; Cheng JL
Chin Med J (Engl); 2020 Jul; 133(14):1639-1648. PubMed ID: 32568867
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Wu QJ; Lv WL; Li JM; Zhang TT; Zhou WH; Zhang Q; Wang JC; Wang QN; Zhang RX; Zhao X; Chen ST; Liu S; Li GH; Cao ZM; Xu L; Chen J
Trials; 2020 Jun; 21(1):482. PubMed ID: 32503608
[TBL] [Abstract][Full Text] [Related]
16. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
17. [Effects of entecavir and Shenxian Yiganling combination therapy on patients with HBeAg-positive chronic hepatitis B for 48 weeks].
Zhang T; Wang Y; Sun KW
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):180-2. PubMed ID: 22574588
[TBL] [Abstract][Full Text] [Related]
18. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
19. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
20. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U
Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
